Ulcerative colitis trials recruiting in Illinois

All Ulcerative colitis trials nationally

Cities in Illinois

Recruiting trials in Illinois

• A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
  NCT06587828 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Skokie
• A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
  NCT06405087 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Illinois: Park Ridge
• A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
  NCT07483073 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Illinois: Chicago
• A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
  NCT07113522 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Illinois: Glenview, Gurnee
• A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
  NCT05076175 · Phase: Phase 2, Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Illinois: Park Ridge
• A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
  NCT06598943 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Illinois: Chicago, Oak Lawn
• A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
  NCT07012395 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Illinois: Chicago
• A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
  NCT06095128 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Illinois: Chicago
• A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
  NCT06581328 · Phase: Phase 4 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Illinois: Downers Grove, Glenview, Lake Barrington, Naperville
• A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
  NCT05442567 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female) · Illinois: Park Ridge
• A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
  NCT06100289 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Illinois: Park Ridge
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT06588855 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · Illinois: Glenview, Gurnee
• A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
  NCT05287126 · Phase: Phase 2 · Ages: 12 Years to 17 Years · Sex: All (male and female) · Illinois: Chicago
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
  NCT06979336 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago
• A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
  NCT06867094 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Illinois: Glenview, Gurnee
• A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
  NCT07071519 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Illinois: Chicago
• A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
  NCT06636656 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Illinois: Gurnee
• An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07184996 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · Illinois: Chicago, Des Plaines, Glenview, Gurnee
• An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
  NCT06398626 · Phase: Not specified · Ages: 18 Years to 64 Years · Sex: All (male and female) · Illinois: Chicago, Naperville
• Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)
  NCT05987852 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 85 Years · Sex: All (male and female) · Illinois: Lake Forest
• LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
  NCT07186101 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Illinois: Belleville, Chicago, Des Plaines, Glenview
• LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
  NCT07415044 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Illinois: Chicago, Des Plaines, Springfield
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
  NCT06937086 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Illinois: Chicago
• STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission
  NCT06693310 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · Illinois: Chicago
• Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies
  NCT07427017 · Phase: Phase 2 · Ages: 18 Years to 85 Years · Sex: All (male and female) · Illinois: Chicago
• Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
  NCT07697456 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Illinois: Oak Lawn
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago
• Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
  NCT05230173 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago